Mainz Biomed (NASDAQ:MYNZ – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Mainz Biomed in a research report issued on Monday, November 25th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.23) EPS.
Mainz Biomed Trading Up 13.8 %
Shares of MYNZ stock opened at $0.26 on Tuesday. Mainz Biomed has a fifty-two week low of $0.19 and a fifty-two week high of $1.79. The business’s 50 day moving average price is $0.26 and its 200-day moving average price is $0.39.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is a Low P/E Ratio and What Does it Tell Investors?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
